{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.4","upperLimit":"98.0","value":"95.6"},{"groupId":"OG001","lowerLimit":"80.2","upperLimit":"96.4","value":"91.4"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.5","upperLimit":"91.0","value":"85.7"},{"groupId":"OG001","lowerLimit":"69.6","upperLimit":"92.9","value":"84.9"}]}],"title":"3 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.2","upperLimit":"82.7","value":"68.5"},{"groupId":"OG001","lowerLimit":"38.4","upperLimit":"81.9","value":"64.6"}]}],"title":"5 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) comprised of all randomized participants. According to the intent to treat principle, participants were analyzed according to the treatment and stratum were assigned at randomization.","reportingStatus":"POSTED","timeFrame":"From the first dose of treatment up to study completion, up to 5 years","title":"Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}